|Assembly Biosciences Inc., of South San Francisco, and Arbutus Biopharma Corp., of Warminster, Pa.||Vebicorvir + AB-729||Hepatitis B virus core inhibitor + GalNAc delivered RNAi therapeutic||Hepatitis B virus infection||Started the 48-week study comparing the 2 drugs plus standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) to each drug individually with a NrtI; primary endpoint is safety and tolerability; secondary endpoint includes reduction of hepatitis B virus (HBV) viral biomarkers such as HBV DNA, HBV pgRNA and HBsAg|
|Innovation Pharmaceuticals Inc., of Wakefield, Mass.||Brilacidin||Dual PDE3/4 inhibitor||Hospitalized COVID-19||Company disclosed details for the ongoing 120-patient study comparing 3 days of treatment with brilacidin to placebo; after an interim review by the data monitoring committee, dosing may be extended to 5 days; primary endpoint is time to sustained recovery through day 29; additional endpoints include duration of hospitalization, time to discharge, all-cause mortality, measurement of disease biomarkers and inflammation-related biomarkers, changes to SARS-CoV-2 viral load as well as other measures|
|Pharvaris NV, of Zug, Switzerland||PHVS-416||Bradykinin-B2-receptor antagonist||Hereditary angioedema due to C1-inhibitor deficiency type 1 and 2||Treated first of 54 patients in the Rapide-1 study comparing 3 dose levels to placebo; primary endpoint is change of the 3-symptom composite visual analogue scale score from pre-treatment to 4 hours post-treatment|
|XNK Therapeutics AB, of Stockholm||Undisclosed||Autologous NK cell-based product||Multiple myeloma||The investigator-sponsored ISA-HC-NK study will compare the NK cells plus Sarclisa (isatuximab, Sanofi SA) to Sarclisa alone as a consolidation treatment following autologous stem cell transplantation|
|Amgen Inc., of Thousand Oaks, Calif., and Astrazeneca plc, of Cambridge, U.K.||Tezepelumab||Monoclonal antibody targeting thymic stromal lymphopoietin||Severe asthma||In the Navigator study, tezepelumab plus standard of care (SOC) produced a 56% reduction in the annualized asthma exacerbation rate (AAER) compared to SOC alone (p<0.001); in patients with baseline eosinophil counts less than 300 cells/μL, AAER was reduced by 41% (p<0.001); in patients with baseline eosinophil counts less than 150 cells/μL, AAER was reduced by 39%; in patients with baseline eosinophil counts of 300 cells/μL or greater, AAER was reduced by 70%|
|Revive Therapeutics Ltd., of Toronto||Bucillamine||Xanthine oxidase inhibitor||Mild to moderate COVID-19||Plans to expand study from 14 clinical sites to up to 50 sites|
|Partner Therapeutics Inc., of Lexington, Mass.||Leukine (sargramostim)||Recombinant human granulocyte-macrophage colony stimulating factor||Hospitalized COVID-19||In the investigator-led Sarpac study, 54% of patients taking sargramostim plus standard of care (SOC) had an improvement in oxygenation of 33% or more from baseline compared to 26% of patients on SOC (p=0.0147)|
For more information about individual companies and/or products, see Cortellis.